Best Practice & Research Clinical Haematology最新文献_第2页

Corrigendum to “Precision immunomodulation: Understanding and harnessing cytokine pathways to treat and prevent immune-related adverse events (irAEs)” [Best Pract Res Clin Haematol 38 2 2025] “精确免疫调节：理解和利用细胞因子途径来治疗和预防免疫相关不良事件（irAEs）”的勘误表[最佳实践Res临床血血学38 2 2025]

IF 2.2 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2025-09-01 Epub Date: 2025-07-18 DOI: 10.1016/j.beha.2025.101648

Matthew J. Hadfield , Ross D. Merkin , Sherin J. Rouhani , Kerry L. Reynolds

引用次数: 0

Research progress of targeted BCMA CAR-T therapy for relapsed/refractory multiple myeloma antigen-negative relapse 靶向BCMA CAR-T治疗复发/难治性多发性骨髓瘤抗原阴性复发的研究进展

IF 2.2 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2025-06-01 Epub Date: 2025-05-15 DOI: 10.1016/j.beha.2025.101632

Lulu Kong , Kailin Xu , Wei Chen

{"title":"Research progress of targeted BCMA CAR-T therapy for relapsed/refractory multiple myeloma antigen-negative relapse","authors":"Lulu Kong , Kailin Xu , Wei Chen","doi":"10.1016/j.beha.2025.101632","DOIUrl":"10.1016/j.beha.2025.101632","url":null,"abstract":"<div><div>Chimeric antigen receptor T cell (CAR-T) therapy targeting B-cell maturation antigen (BCMA) has emerged as a novel and effective modality for the treatment of relapsed or refractory multiple myeloma (RRMM), achieving remarkable therapeutic outcomes. However, relapse remains a major problem impeding the long-term efficacy of this therapy, with antigen-negative relapse being a particularly challenging issue. The mechanisms underlying BCMA antigen-negative relapse encompass a spectrum of phenomena, including diminished or lost tumor antigen expression, BCMA shedding, impaired antigen presentation, trogocytosis, antigen mutations, and alternative splicing. To overcome the problem of antigen-negative relapse in BCMA CAR-T therapy, a variety of strategies are being explored. These include dual/multi-specific CAR-T cell therapy, combination therapies with antibody-drug conjugates (ADCs) or bispecific T-cell engagers (BiTEs), integration with hematopoietic stem cell transplantation (HSCT), identification of novel targets, and the development of innovative cell therapies such as CAR-NK and CAR-M (CAR-Macrophage). Additionally, the optimization of CAR-T cells through gene editing technologies to enhance their durability and anti-tumor activity is a burgeoning area of research. In future, targeted BCMA CAR-T therapy is poised to place greater emphasis on individualization and precision medicine, combining multiple therapeutic approaches to reduce the incidence of relapse, thereby improving treatment efficacy and longevity.</div></div>","PeriodicalId":8744,"journal":{"name":"Best Practice & Research Clinical Haematology","volume":"38 2","pages":"Article 101632"},"PeriodicalIF":2.2,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144116270","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cytokines in transplantation tolerance 细胞因子在移植耐受中的作用

IF 2.2 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2025-06-01 Epub Date: 2025-05-08 DOI: 10.1016/j.beha.2025.101627

Andre Souffrant , Avery Wilson , Bryar Hansen , Katsuhiro Tomofuji , Ryo Otsuka , Gilles Benichou , Thomas Spitzer , Tatsuo Kawai

{"title":"Cytokines in transplantation tolerance","authors":"Andre Souffrant , Avery Wilson , Bryar Hansen , Katsuhiro Tomofuji , Ryo Otsuka , Gilles Benichou , Thomas Spitzer , Tatsuo Kawai","doi":"10.1016/j.beha.2025.101627","DOIUrl":"10.1016/j.beha.2025.101627","url":null,"abstract":"<div><div>Transplantation tolerance is an immunologic state in which a transplant recipient's immune system does not mount a destructive immune response to an allograft. Tolerance offers an alternative to lifelong immunosuppression, potentially extending both allograft and patient survival by reducing transplant-related morbidity. Currently, the only clinically relevant approaches to achieve allograft tolerance rely on induction of donor hematopoietic chimerism through bone marrow or hematopoietic cell transplantation.</div><div>There are two known types of T cell tolerance to alloantigens – central and peripheral. In central tolerance, alloantigen presentation in the thymic medulla results in clonal deletion of alloreactive immature lymphocytes. Peripheral tolerance is mediated by development of tolerogenic cell populations such as immature dendritic cells and regulatory T cells which suppress or delete alloreactive immune cells in the periphery.</div><div>As the signaling molecules secreted by immune cells to orchestrate immune responses, cytokines are important in development of both central and peripheral tolerance and are critical in mediating both allograft rejection and tolerance. Understanding the immunology underlying the effects of cytokines on the immune system can help us to better understand their role in tolerance and to leverage that understanding to more reliably and safely induce transplantation tolerance.</div></div>","PeriodicalId":8744,"journal":{"name":"Best Practice & Research Clinical Haematology","volume":"38 2","pages":"Article 101627"},"PeriodicalIF":2.2,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144130798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cytokines in hematology, hematopoietic cell transplantation and immune effector cell therapy: Preface 细胞因子在血液学、造血细胞移植和免疫效应细胞治疗中的应用：前言

IF 2.2 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2025-06-01 Epub Date: 2025-05-10 DOI: 10.1016/j.beha.2025.101629

Thomas R. Spitzer MD, Hillard M. Lazarus MD, FACP, Robert Peter Gale MD, PhD, DSc(hc), FACP, FRCP, FRCPI(hc), FRSM

引用次数: 0

Advancing MSC therapy: The next generation of potent mesenchymal stromal cells for systemic autoimmune rheumatic diseases 推进MSC治疗：下一代强效间充质间质细胞治疗系统性自身免疫性风湿病

IF 2.2 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2025-06-01 Epub Date: 2025-05-02 DOI: 10.1016/j.beha.2025.101626

Hulya Bukulmez , Kristin B. Highland , Rujman Khan , Gary S. Gilkeson , Steven N. Emancipator

引用次数: 0

Precision immunomodulation: Understanding and harnessing cytokine pathways to treat and prevent immune-related adverse events (irAEs) 精确免疫调节：理解和利用细胞因子途径治疗和预防免疫相关不良事件（irAEs）

IF 2.2 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2025-06-01 Epub Date: 2025-04-16 DOI: 10.1016/j.beha.2025.101625

Matthew J. Hadfield , Ross D. Merkin , Sherin J. Rouhani , Kerry L. Reynolds

{"title":"Precision immunomodulation: Understanding and harnessing cytokine pathways to treat and prevent immune-related adverse events (irAEs)","authors":"Matthew J. Hadfield , Ross D. Merkin , Sherin J. Rouhani , Kerry L. Reynolds","doi":"10.1016/j.beha.2025.101625","DOIUrl":"10.1016/j.beha.2025.101625","url":null,"abstract":"<div><div>The utilization of immune checkpoint inhibitors has fundamentally changed both the treatment landscape for a multitude of malignancies as well as our understanding of cancer biology. Despite profound advancements, the utilization of these drugs is often limited by the development of immune-related adverse events (irAEs), characterized by off-target toxicity to healthy tissue secondary to treatment. Currently, irAEs are often treated with high-dose corticosteroids, with additional immunosuppressive agents added for severe or refractory irAEs. Cytokine pathway inhibitors, particularly anti-TNFa and anti-IL-6R antibodies, are commonly used as second-line immunosuppression. The efficacy of blocking these pathways in treating irAEs, as well as their potential impact on anti-tumor response, will be discussed. Additionally, this review will also explore other cytokines implicated in irAE pathophysiology, including interleukin-17 (IL-17), interleukin-23 (IL-23), interleukin-4/13 (IL-4/IL-13) and interleukin-5 (IL-5) which play important roles in the inflammatory cascades underlying specific irAEs such as colitis, dermatitis, and eosinophilia-related toxicities.</div></div>","PeriodicalId":8744,"journal":{"name":"Best Practice & Research Clinical Haematology","volume":"38 2","pages":"Article 101625"},"PeriodicalIF":2.2,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144470748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cytokines and immune effector cell therapy 细胞因子和免疫效应细胞疗法

IF 2.2 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2025-06-01 Epub Date: 2025-05-08 DOI: 10.1016/j.beha.2025.101628

Alexandra Haugh, Matthew J. Frigault

引用次数: 0

Applications and prospects of molecularly targeted drugs combined with CAR-T cell therapy to treat multiple myeloma 分子靶向药物联合CAR-T细胞治疗多发性骨髓瘤的应用与展望

IF 2.2 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2025-06-01 Epub Date: 2025-05-15 DOI: 10.1016/j.beha.2025.101633

Yan Xu, Jianping Mao

引用次数: 0

Endogenous and exogenous cytokines: An overview and introduction 内源性和外源性细胞因子：概述和介绍

IF 2.2 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2025-06-01 Epub Date: 2025-04-13 DOI: 10.1016/j.beha.2025.101615

Thomas R. Spitzer , Hillard M. Lazarus

{"title":"Endogenous and exogenous cytokines: An overview and introduction","authors":"Thomas R. Spitzer , Hillard M. Lazarus","doi":"10.1016/j.beha.2025.101615","DOIUrl":"10.1016/j.beha.2025.101615","url":null,"abstract":"<div><div>Cytokines are ubiquitous small proteins, secreted by virtually all leukocytes and other immune effector cells, that interact with other cytokines and effector and regulatory cells to direct innate and adaptive immunity. Six broad categories of cytokines have been described, with functions ranging from stimulation of immunity and inflammation by cytokines produced by white blood cells (interleukins) to impacting the migration of immune effector cells to sites of inflammation and tissue injury (chemokines). When secreted in excess, or when there exists an imbalance between proinflammatory and anti-inflammatory cytokines, diseases ranging from sepsis to organ transplant rejection to autoimmune disorders occur. The development of exogenous cytokines for therapeutic use, similar or identical to naturally occurring cytokines, has resulted in advances in the management of cancer and autoimmune diseases. On the other hand, the development of inhibitors of cytokines has resulted in the ability to control of a growing list of inflammatory, neoplastic, autoimmune, and allergic conditions. Future investigations should continue to explore the manner cytokines are exploited for therapeutic purpose or are used as inhibitors to interrupt the pathobiological mechanisms of disease.</div></div>","PeriodicalId":8744,"journal":{"name":"Best Practice & Research Clinical Haematology","volume":"38 2","pages":"Article 101615"},"PeriodicalIF":2.2,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143844629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immune reconstitution following allogeneic hematopoietic cell transplantation and CAR-T therapy: dynamics, determinants, and directions 同种异体造血细胞移植和CAR-T治疗后的免疫重建：动力学、决定因素和方向

IF 2.2 4区医学

Best Practice & Research Clinical Haematology Pub Date : 2025-06-01 Epub Date: 2025-05-16 DOI: 10.1016/j.beha.2025.101634

Weijia Fu , Jiahao Chen , Xiaoxia Hu

{"title":"Immune reconstitution following allogeneic hematopoietic cell transplantation and CAR-T therapy: dynamics, determinants, and directions","authors":"Weijia Fu , Jiahao Chen , Xiaoxia Hu","doi":"10.1016/j.beha.2025.101634","DOIUrl":"10.1016/j.beha.2025.101634","url":null,"abstract":"<div><div>Immune reconstitution (IR) is a dynamic and sequential process that occurs after allogeneic hematopoietic cell transplantation (allo-HCT) and cellular therapies, involving the gradual recovery of both innate and adaptive immune compartments. The success of IR is a critical determinant of clinical outcomes, including the risk of graft-versus-host disease and graft-versus-leukemia effects. In the context of allo-HCT, IR shaped by various factors, including transplantation modalities, conditioning regimens, therapeutic interventions, and post-transplant strategies. The kinetics and quality of IR following chimeric antigen receptor T-cell (CAR-T) therapy are also shaped by several factors, such as lymphodepleting chemotherapy, CAR construct design, and the patient's baseline immune status. In particular, B-cell–targeted CAR-T therapy frequently results in B-cell aplasia, hypogammaglobulinemia, and immune exhaustion, necessitating improved monitoring and post-treatment interventions. These immunologic effects highlight the need for improved post-treatment monitoring and supportive interventions to reduce infection risk and ensure sustained immune recovery. To better characterize IR across both allo-HCT and CAR-T settings, advanced immune profiling technologies, such as flow cytometry and single-cell RNA sequencing, are providing new insights into the dynamics of immune recovery. Here, we summarize current knowledge on IR kinetics and evaluate the impact of different transplant and CAR-T settings. We then discuss personalized strategies to optimize immune monitoring and therapeutic approaches for recipients of allo-HCT and CAR-T therapies.</div></div>","PeriodicalId":8744,"journal":{"name":"Best Practice & Research Clinical Haematology","volume":"38 2","pages":"Article 101634"},"PeriodicalIF":2.2,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144106976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0